Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash

Key Points Boston-based MPM Bioimpact sold 313,571 shares of MoonLake Immunotherapeutics in the third quarter, reducing the position by about $14.8 million. The move marked a full exit for MPM, which reported holding no MLTX shares at quarter-end. The position accounted for 2.6% of the fund’s AUM as of the prior quarter. These 10 stocks could mint the next wave of millionaires › On November 14, MPM BioImpact reported in a U.S. Securities and Exchange Commission filing that it sold out its MoonLak ...